**Introduction**

The histiocytoses are a diverse group of hematologic disorders defined by the pathologic infiltration of normal tissues by cells of the mononuclear phagocyte system (MPS). The heterogeneity of this family of disorders, a direct result of the biologic variability of the cells of the MPS and the tissues they inhabit, makes the study of these diseases one of the most intriguing yet complex areas of modern hematology.

Advances in basic hematology and immunology over the last two decades have significantly enhanced our understanding of the histiocytic disorders. It is now accepted that the pathogenic cells central to the development of the histiocytoses arise from a common hematopoietic progenitor. More specifically, the ability to molecularly identify the hematopoietic cells has enabled us to classify the histiocytoses based on the cellular basis of the disease and to define the natural history of these disorders.\(^1,2\) These pathologic cells phenotypically resemble immature mononuclear phagocytes at specific stages of differentiation.\(^7\)

The Histiocyte Society, formed in 1985, has served as a forum for enhanced collaboration between international histiocytosis experts. Since its inception, the Histiocyte Society has used the cellular based classification of the histiocytoses as a guideline for therapeutic studies, which have in turn significantly advanced our ability to care for patients, improve their outcomes and advance the scientific understanding of the histiocytoses. In this chapter we use the cellular classification of histiocytic disorders, as adopted by the Histiocyte Society, to present each subgroup of this family of disorders, describe their natural history and present current therapeutic approaches and outcomes.

**Histiocytes and normal immune function**

The MPS is a system of cells whose primary function consists of phagocytosis of foreign material, antigen processing, and antigen presentation to lymphocytes. This system, recognized in part through the work of Metchnikoff, was originally termed the reticuloendothelial system by Ludwig Aschoff in the early part of the twentieth century.\(^4\) The central cell of this system, the mononuclear phagocyte or histiocyte, represents a group of anatomically and functionally distinct cells arising from a common precursor, the hematopoietic stem cell.

Cells of the MPS have a wide range of morphologic, anatomic and functional characteristics that make classification of this system difficult. Our ability to identify and classify the cells of the MPS has advanced in parallel with developments in basic hematology and immunology. As our knowledge of the molecular biology regulating hematopoiesis has improved, we have been able to identify specific characteristics that have enabled us to classify the cells of the MPS. Mononuclear phagocytes can be divided into two major classes, macrophages and dendritic cells. This classification is based on (i) phagocytic and antigen-presenting abilities, (ii) morphologic and ultrastructural appearance, (iii) expression of common enzymes, (iv) presence of common cell surface antigens, and (v) common regulatory cytokine and transcription factor networks.

Tissue macrophages are derived from bone marrow hematopoietic precursors and can arise directly from circulating peripheral blood monocytes. These cells enter different tissues and assume tissue-appropriate morphology based on the local cytokine milieu. Once established in various tissues, macrophages typically do not have the ability to self-renew extensively except possibly under specialized microenvironments such as in the lungs and pituitary. Tissue inflammation increases the influx of monocytes, which in turn give rise to macrophages with an immunologically activated phenotype. Inflammatory stimuli can also further enhance the local replication of macrophages in cases of tissue injury.\(^5,6\) Regardless of location, macrophage growth and differentiation is a tightly controlled process regulated by specific growth factors.
Interleukin (IL)-3, IL-4, IL-13, granulocyte–macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) are all stimulatory cytokines with a major role in macrophage development and differentiation. M-CSF activity is especially essential for appropriate macrophage growth and differentiation. The M-CSF receptor, a product of the c-fms protooncogene, is expressed by most of the MPS.8 When bound by M-CSF, the receptor dimerizes, leading to the activation of its kinase domain and initiation of downstream signaling pathways. The signaling cascade initiated by the binding of M-CSF to its receptor is essential for the proliferation of progenitor cells of the monocyte–macrophage lineage, differentiation and their long-term survival. Information regarding the role of M-CSF primarily arises from studies of mice deficient in the M-CSF receptor. Despite their severe monocyte–macrophage deficiencies, mice maintain normal levels of dendritic cells in their spleens and skin, thus demonstrating an alternative and M-CSF-independent pathway for their development. The GM-CSF receptor, also present on most members of the MPS, plays a critical role in normal cellular homeostasis, differentiation and function. There is also a positive survival effect of stem cell factor (the ligand for the c kit receptor) and FLT3 ligand and its cognate receptor FLT3, as well as inhibitory roles for interferon (IFN)-α/β, transforming growth factor (TGF)-β and leukocyte inhibitory factor.8 The phenotypic and functional heterogeneity of macrophages as a group is attributed to the tissue-specific effects of cytokine stimulation on the multipotent mononuclear phagocytic system.1

Macrophages are ubiquitously distributed in the body and are heavily represented in mucosal tissues and other potential portals of entry for microorganisms, where they function in both innate and adaptive immunity. They have the capacity to phagocytose foreign organisms and release inflammatory cytokines that in turn recruit other inflammation-associated cell types. Macrophages also maintain the ability to process and present antigenic portions of foreign organisms to T lymphocytes, although not as effectively as dendritic cells. Tissue macrophages have significant functional variability depending on their location within the body. Peritoneal and soft tissue macrophages, Kupffer cells, foam cells, synovial cells, osteoclasts and microglial cells are all members of this class of cells and contribute to tissue growth, repair and remodeling. A distinguishing feature of macrophages is expression of the enzymes lysozyme, α1-antitrypsin, α1-antichymotrypsin, aminopeptidase, peroxidase, alkaline phosphatase, α-naphthol chloroacetate esterase and β-glucuronidase.8

The second class of mononuclear phagocytes, the dendritic cells, was first described by Steinman and Cohn in 1973. These cells were named because of their unique membranous, and often branch-like, cytoplasmic aberrations (from the Greek word for tree, δέντρον).15 Dendritic cells are primarily located in skin, mucosa, bone marrow, spleen, thymus and lymph nodes. This group of cells also includes dendritic cells of the lymphoid follicle, the interdigitating dendritic cells of the paracortical regions of lymph nodes, and Langerhans cells of the skin and other organs. Langerhans cells, originally identified by Paul Langerhans in 1869, are bone marrow–derived cells that present antigens to T lymphocytes. Langerhans cells, along with Birbeck granules, pattern of interdigitating dendritic cells and their ability to migrate, provides a physical and functional link between peripheral tissues and secondary lymphoid organs where lymphocyte maturation takes place. Langerhans cells and the interdigitating dendritic cells present antigens to stimulate primary T-lymphocyte responses. It is well established that the precursor to most dendritic cells is bone marrow–derived but the biologic significance of this differentiation scheme is still not completely defined as a significant amount of the data has been derived from in vitro studies. Other distinguishing characteristics of mature dendritic cells include (i) high expression levels of class II major histocompatibility complex (MHC) antigens and costimulatory receptors, making them potent at antigen presentation, (ii) demonstrable triphosphatase and α-mannosidase expression and (iii) distinct pan- and cell surface-staining pattern with peanut agglutinin that contrasts with the diffuse staining pattern demonstrated by macrophages.16

The development of methods to generate monoclonal antibodies in the 1970s and 1980s significantly enhanced our knowledge of the MPS. The F4/80 antibody, a murine pan-macrophage antibody, was one of the first well-recognized markers of the MPS. This antibody recognizes members of a gene family that includes the human epidermal growth factor (EGF) module-containing mucin-like hormone receptor 1 and CD97. The presence of this antigen on the surface of tissue macrophages and dendritic cells helped confirm the existence of a common origin for the diverse lineages that comprises the MPS. Other markers such as S100β subunit, CD1a and Langerin, are found on Langerhans cells but are usually absent on macrophages are used clinically to distinguish...
between the cells of the MPS. Conversely, monocytes and macrophages express nonspecific carcinoembryonic cross-reacting antigen, CD4 antigen, nonspecific esterase and the cell surface marker CD11c (Leu-M5). Both types of cells express class II MHC molecules and T-lymphocyte costimulatory receptors. These markers, in particular S100, CD1a and Langerin are utilized clinically to distinguish between the different histiocytic syndromes. Figure 15.1 denotes the lineage relationships thought to define the differentiation of cells of the MPS and the developmental stages from which various histiocytic disorders are believed to arise.

The development and differentiation of the cells of the MPS, much like other hematopoietic lineages, is driven by a tightly regulated pattern of gene expression governed by distinctive sets of transcription factors that control cell proliferation and differentiation. The main transcription factor families implicated in the development of this system include the myb family, the Ets family and the C/EBP family. PU.1, a member of the Ets family, plays a central role in monocyte-macrophage lineage as demonstrated by PU.1 knockout mice which lack functional monocytes and tissue macrophages and display significant dendritic cell abnormalities.19,21 This has become clearer recently as it has been shown that PU.1 regulates the expression of c-fms, the gene coding for the M-CSF receptor, in addition to other critical genes such as FcγRI, FcγRIIA, scavenger receptors type 1 and 2, CD11b, CD18 and CD14.21

In summary, the MPS represents a continuum of functionally distinct cell types that arise from common bone marrow progenitors and differentiate along specific lineage pathways based on environmental stimuli and intrinsically regulated gene expression patterns. The result is the generation of a diverse group of cell types with distinct but often overlapping biologic functions. Understanding this biologic heterogeneity is an important key to more accurate diagnosis and treatment of the histiocytic disorders.

**Modern classification of histiocytic disorders**

As proposed in 1987,1 the histiocytic disorders can be
classified into three classes based on the pathologic cells present within the lesions.
  • Class I: Langerhans cell histiocytoses and other dendritic cell disorders.
  • Class II: non-Langerhans cell histiocytoses primarily consisting of hemophagocytic lymphohistiocytosis.
  • Class III: malignant histiocytoses.

This system was revised in 1997 by the World Health Organization’s Committee on Histiocytic/Reticulum Cell Proliferations and the Reclassification Working Group of the Histiocyte Society. The central theme of this reclassification schema consisted of distinguishing the clearly malignant histiocytoses from the remaining subtypes, the so-called “disorders of varied biological behavior”.

Acute myelomonocytic leukemia (FAB M4), acute monocytic leukemia (FAB M5), chronic myelomonocytic leukemia and the histiocytic sarcomas are all classified in the malignant histiocytoses category. The disorders of varied biological behavior continued to be divided into dendritic cell-related disorders (class I) and macrophage-related disorders (class II). The dendritic cell-related disorders include Langerhans cell histiocytosis, the most common type in this class, in addition to other less common subtypes. Primary and secondary hemophagocytic lymphohistiocytosis, in addition to sinus histiocytosis with massive lymphadenopathy (also known as Rosai-Dorfman disease), are the two major types of macrophage-related histiocytosis discussed in this chapter. This classification schema is summarized in Table 15.1. The remainder of this chapter focuses on the pathophysiology, clinical presentation, treatment and outcomes of the principal histiocytoses.

### Disorders of varied biological behavior: dendritic cell-related (class I) histiocytoses

#### Langerhans cell histiocytosis

**Biology**

Langerhans cell histiocytosis (LCH) is the most common member of the dendritic cell-related histiocytic disorders. LCH includes the previously identified disorders known as eosinophilic granuloma, Abt–Letterer–Sive disease and Hand–Schüller–Christian disease. The pathologic similarity of these disorders was first noted by Sidney Farber in 1941 and by the 1950s, as a result of the work of Lichtenstein, these disorders were collectively referred to as histiocytosis X. The persistent use of this historical terminology in modern medical vernacular is indicative of its significance and utility for cataloging patient symptomatology. Regardless of the historical eponyms, the pathologic hallmark of all subtypes of LCH is the abnormal proliferation and accumulation of immature Langerhans cells along with macrophages, lymphocytes and eosinophils that together form granuloma-tous lesions. Although the biologic role of LCH cells in the pathogenesis of LCH remains unclear, it is now generally accepted that the close physical interaction between these cells and other cell types present in these lesions is associated with an abnormal cytokine and chemokine microenvironment that underlies the pathogenesis of LCH.

In 1973 Nezelof et al. provided definitive evidence for the phenotypic similarity of normal Langerhans cells and LCH cells, including a description of the presence of Birbeck granules in both cell types. However, LCH cells, in contrast to normal Langerhans cells, typically lack dendritic cell extensions and have a rounded appearance with distinct cellular margins. These cells express CD1a, S100 and Langerin (CD207) but not the typical markers of more mature dendritic cells such as CD83, CD86 and DC-Lamp (Fig. 15.2). In addition, these cells express CD40 and intracellular MHC class II proteins but are inefficient antigen-presenting cells. When LCH cells are exposed in vitro to CD40L, they acquire markers of dendritic cell maturation. LCH cells also express CCR6, the receptor for the proinflammatory chemokine CCL20/MIP3α, a characteristic of immature dendritic cells. Furthermore, these cells have been shown to also secrete CCL20/MIP3α, CCL5/RANTES and CXCL11/I-TAC, all of which are believed to function in recruiting additional LCH cells, eosinophils and T cells to LCH lesions. Of note, the co-expression of CCR6 and CCR7 on LCH cells has also been reported. This may be suggestive of the pathological

<table>
<thead>
<tr>
<th>Class I: dendritic cell histiocytoses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Langerhans cell histiocytosis</td>
</tr>
<tr>
<td>Secondary dendritic cell processes</td>
</tr>
<tr>
<td>Juvenile xanthogranuloma and related disorders</td>
</tr>
<tr>
<td>Erdheim–Chester disease</td>
</tr>
<tr>
<td>Solitary histiocytomas of various dendritic cell phenotypes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Class II: nondendritic cell histiocytoses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary hemophagocytic lymphohistiocytosis</td>
</tr>
<tr>
<td>Familial hemophagocytic lymphohistiocytosis</td>
</tr>
<tr>
<td>Secondary hemophagocytic lymphohistiocytosis</td>
</tr>
<tr>
<td>Infection associated</td>
</tr>
<tr>
<td>Malignancy associated</td>
</tr>
<tr>
<td>Rosai-Dorfman disease with massive lymphadenopathy</td>
</tr>
<tr>
<td>Solitary histiocytoma with macrophage phenotype</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Class III: malignant histiocytoses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monocytic related</td>
</tr>
<tr>
<td>Leukemias (FAB and revised FAB classification)</td>
</tr>
<tr>
<td>Monocytic leukemia M5A and M5B</td>
</tr>
<tr>
<td>Acute myelomonocytic leukemias M4</td>
</tr>
<tr>
<td>Chronic myelomonocytic leukemias</td>
</tr>
<tr>
<td>Extramedullary monocytic tumor or sarcoma</td>
</tr>
<tr>
<td>Dendritic cell-related histiocytic sarcoma</td>
</tr>
<tr>
<td>Macrophage-related histiocytic sarcoma</td>
</tr>
</tbody>
</table>

**FAB, French–American–British.**
maturational arrest of these cells. Immunohistochemical and in situ hybridization data also demonstrate abnormal release of specific cytokines, such as GM-CSF, IL-10, TGF-α/β, IFN-γ and tumor necrosis factor (TNF)-α, by lesional cells in LCH. The cytokine abnormalities noted in LCH lesions are hypothesized to magnify the local autocrine and paracrine effects of these cells, resulting in a focal “cytokine storm”. These cytokines also cause local tissue damage and contribute to the systemic symptoms such as fever, skin rashes and hypotension. Unlike hemophagocytic lymphohistiocytosis, there is no clear-cut evidence for systemic cytokine overproduction in most cases of LCH.

Despite our improved understanding of the molecular events involved in the pathophysiology of LCH, its etiology remains undetermined. Infectious, inflammatory and neoplastic mechanisms have all been postulated to play an etiologic role in LCH, but the relative contribution of each process to the development of the disease remains controversial. Implications of the variable expression pattern of MDM2, p53 and p21 and the strong expression of TGF-β seen in LCH remain unclear. Based on this data, most experts now agree that LCH is the result of complex interactions between environmental factors and intrinsic genetic changes leading to a clonal proliferative disorder of immature Langerhans cells with variable clinical behavior.

Incidence and epidemiology

LCH has been historically considered a disease of young children, with a peak occurrence between the ages of 1 and 3 years. A Danish study estimated the incidence of LCH in children less than 15 years old to be 0.54 per 100 000 children per year. However, this is considered to be an underestimation as a proportion of children are believed to go undiagnosed. A Swedish study has estimated an incidence of...
Histiocytic disorders

LCH also shows a predilection for males, with a female to male ratio of 1:1.2–2.1. It is also now well recognized that the incidence of LCH in adulthood is likely to be underestimated. This has been attributed to the multiple subspecialties involved in the care of patients with this disease depending on the involved organ system in addition to incorrect diagnoses. This problem is now being addressed by the Histiocyte Society as more emphasis is being placed on studies of adult subjects, including the most recent adult therapeutic study, LCH A-1.

A case–control epidemiologic study has suggested associations between the diagnosis of LCH and maternal urinary tract infections as well as feeding problems, medication use and blood transfusions during the first 6 months of life. A subsequent study has demonstrated a significant odds ratio for postnatal infections, diarrhea and vomiting, as well as medication use in multisystem LCH, while single-system LCH was associated with thyroid disease or a family history of thyroid disease. The results of these studies are for the most part inconclusive with regard to any etiologic associations. However, it has to be pointed out that none of the studies performed has noted a geographical or seasonal clustering of cases of LCH, making a common infectious etiology unlikely.

Clinical presentation and therapy

LCH represents a wide variety of different clinical entities recognized to be pathologically the same. LCH is clinically subclassified by the degree and location of organ involvement: localized single-system disease, multifocal single-system disease and multisystem disease. The location of involvement has been shown to be of prognostic importance, with bone marrow, pulmonary, spleen and liver involvement denoted as “risk organs” while involvement of cranial bones or spine with extradural soft tissue extension is considered to be “central nervous system (CNS) risk.” This clinical classification schema currently serves as the basis for risk stratification of LCH treatment protocols.

At the time of diagnosis, a complete work-up should be performed to establish the full extent of disease and delineate risk-based therapy (Table 15.2). The work-up should include detailed history and physical examination, complete blood count and differential, metabolic panel including liver and renal function tests, bone scan, skeletal survey and chest radiograph. Urine analysis should also be performed to assess for diabetes insipidus and possible hypothalamic–pituitary involvement. Additional studies such as water deprivation test, antidiuretic hormone levels or other endocrinologic examinations evaluating hypothalamic–pituitary function may be necessary depending on a patient’s clinical presentation. Magnetic resonance imaging (MRI) of the brain with gadolinium contrast is becoming a more common part of the staging work-up of “CNS-risk” patients because of the recognition of significant CNS involvement. Bone marrow studies, computed tomography (CT) of the chest and pulmonary function tests should also be performed as clinically indicated to evaluate risk-organ involvement. The role of positron emission tomography remains undefined, but is a potentially promising imaging approach.

Localized LCH involving skin, lymph node or skeleton usually carries a good prognosis. Lesions of bone, a condition often referred to as eosinophilic granuloma, usually present as a painful swelling. These lesions appear radiographically as “punched-out” sites and most commonly affect the calvarium (Fig. 15.3), although they can involve any part of the skeleton. Vertebra plana, or a collapsed vertebra, is a common presentation of this disease process (Fig. 15.4). Single bone lesions rarely need therapy beyond biopsy or curettage, except in the case of severe symptoms or danger of organ dysfunction, such as spinal cord compression or loss of vision. Treatment options for these patients with nonemergency single bone lesions that recur or remain clinically problematic after surgery include nonsteroidal antiinflammatory agents or local steroid injections and, rarely, local low-dose radiation therapy (40–80 cGy). Full surgical resection (i.e., performing a “cancer operation”) of these single bone lesions, especially when other vital structures could be compromised as a result of such an operation, is not typically necessary.

Skin disease typically involves the scalp, retroauricular area, neck, upper chest, axilla and groin. This rash can vary from maculopapular to more eruptive and even nodular in appearance (Fig. 15.5). In some patients, the rash can be quite erosive and a risk factor for serious superinfection. Therapy

| Table 15.2 | Risk groups as defined by the LCH-III protocol (adapted from the Histiocyte Society LCH-III study). |
| Group 1: multisystem “risk” patients | Multisystem patients with involvement of one or more “risk” organs (i.e., hematopoietic system, liver, spleen or lungs) |
| Group 2: multisystem “low-risk” patients | Multisystem patients with multiple organs involved but without involvement of “risk” organs |
| Group 3: single-system “multifocal bone disease” and localized “special site” involvement | Patients with multifocal bone disease (i.e., lesions in two or more different bones) Patients with localized special site involvement, such as “CNS-risk” lesions with intracranial soft tissue extension or vertebral lesions with intraspinal soft tissue extension |
Chapter 15

for isolated skin disease typically involves topical steroids or, in some steroid-refractory cases, topical nitrogen mustard, PUVA or short-wave ultraviolet light without psoralen. Systemic steroids and vinblastine are reserved for extensive single-system disease, including skin involvement, usually with good outcomes.38

In contrast to localized LCH, systemic therapy is indicated in patients with multisystem LCH. The most common presentation of multifocal LCH includes diffuse skin and multifocal bone involvement. The oral cavity, lymph nodes and, to a lesser extent, the lungs, liver and brain are other common sites of involvement in this disease. Oral cavity involvement can lead to infiltrative lesions with ulceration as well as erosion of the mandible or maxilla, leading to “floating” teeth. Figure 15.6 demonstrates the characteristic CT findings of lung involvement. Diabetes insipidus, with pituitary involvement (Fig. 15.7), is the most common manifestation of CNS involvement in LCH and is reported in 5-30% of patients. The triad of lytic skull lesions, exophthalmos and diabetes insipidus, historically referred to as Hand–Schüller–Christian disease, is not commonly observed at the time of diagnosis, although the chronic waxing/waning course is frequently seen in this group of patients. Risk factors for the development of diabetes insipidus have been reported to include the presence of multisystem disease and craniofacial lesions, especially involving the orbit, ear and oral cavity.47 In addition to acute CNS involvement, patients with LCH may develop a severe neurodegenerative process involving loss of motor functions and cognition. This syndrome characteristically involves the cerebellum, pons and midbrain, often in a symmetric pattern (Fig. 15.8).48-50 The clinical severity of neurodegenerative-associated LCH can be independent of radiographic findings or progression.48-51 There are currently no effective means of ameliorating the progression of this process. Liver involvement is another complication of LCH that portends a poor prognosis. Transaminitis and hyperbilirubinemia are the hallmarks of acute liver involvement in LCH. Patients with hepatic LCH or with multisystem disease appear to have a higher risk of developing sclerosing cholangitis that can, in turn, lead to hepatic fibrosis, liver failure and the need for liver transplantation.

Fig. 15.3 Radiograph of skull of a patient with Langerhans cell histiocytosis showing multiple lytic lesions (white arrows).

Fig. 15.4 Magnetic resonance image depicting a vertebra plana secondary to involvement of the vertebral body with Langerhans cell histiocytosis (white arrow).
In addition to site of involvement, age has been thought to be an important prognostic factor in LCH, with younger patients having a significantly higher mortality rate. However, more recent clinical trial data have shown that response to initial (6–12 weeks) therapy with vinblastine and steroids is the most powerful prognostic factor, outweighing even age. Abt–Letterre–Siwe disease is a historical eponym used to describe systemic LCH characterized by extensive skin, bone marrow, spleen, liver and lung involvement; it is usually observed in children less than 2 years old. Oral cavity and gastrointestinal involvement are other commonly seen manifestations of this severe form of LCH. Patients typically suffer from intractable fevers, failure to thrive and, in later phases of the disease, severe pancytopenia and hepatic failure leading to hemorrhage and sepsis. Abt–Letterre–Siwe disease carries a particularly poor prognosis in patients with
advanced hematopoietic involvement who do not show a good response to initial therapy. Patients with Abt–Letterer–Siwe disease should undergo a full evaluation for congenital and acquired immunodeficiency syndromes in addition to infectious etiologies as part of their diagnostic work-up.

It is critical that pulmonary involvement as part of multisystem disease be distinguished from isolated pulmonary LCH (PLCH). PLCH is distinguishable from other forms of LCH by its almost exclusive occurrence in young adults and close association with smoking. PLCH can cause severe inter-

\[ \text{Fig. 15.6 Involvement of the lung in Langerhans cell histiocytosis. (a) Acute nodular involvement; (b) cystic changes often associated with chronic involvement. Photograph (b) courtesy of Dr William Cumming, Department of Radiology, University of Florida School of Medicine, Gainesville, FL, USA.} \]

\[ \text{Fig. 15.7 Magnetic resonance image of pituitary involvement in Langerhans cell histiocytosis: (a) sagittal view; (b) coronal view; (c) horizontal view.} \]
Histiocytic disorders

Interstitial lung disease, cor pulmonale and eventual respiratory failure necessitating lung transplantation. The first line of therapy for PLCH remains smoking cessation, followed in some patients with steroids. The role of chemotherapy in PLCH remains uncertain as prospective data are not available. The use of 2-chlorodeoxyadenosine (2-CDA) has shown some promise in PLCH, although this therapy is reserved for patients with refractory disease and has only shown anecdotal success.52–54 The Histiocyte Society trial for adults with LCH includes patients with PLCH.

Patients with multisystem LCH have been demonstrated to benefit from systemic chemotherapy. The current therapeutic regimens evolved from work originally performed in the 1970s and 1980s. Several studies during that time demonstrated that single-agent therapy with drugs such as methotrexate, vincristine, vinblastine, etoposide, mercaptopurine and prednisone was effective treatment for LCH. These trials were subsequently followed by the larger studies (AIEOP-CNR-HX and DAL-HX 83/90), all of which used regimens with multiple agents. These studies demonstrated response rates of 60–90% using combinations of vinblastine and/or etoposide plus prednisone. These studies also demonstrated that patients with extensive disease and organ dysfunction had significantly higher mortality and recurrence rates.53,58

The AIEOP-CNR-HX and DAL-HX 83/90 studies were then followed by the first international, prospective, randomized study, LCH-I, which also represented the first international clinical trial of the Histiocyte Society. The results of this study demonstrated that patients randomized to treatment with etoposide plus steroids did not have a better outcome than those randomized to receive vinblastine plus steroids. In addition, this study revealed that response at 6 weeks was strongly predictive of overall outcome. For example, patients without a response to therapy after 6 weeks had a survival rate of less than 40% at 5 years. Another critical outcome of this study was the confirmation of earlier work by Lahey that patients older than 2 years of age and without pulmonary, hepatosplenic or hematopoietic involvement had an excellent prognosis, with a response rate of 90% and survival of 100% at 6 years.57,58 In comparison with the AIEOP-CNR-HX and DAL-HX 83/90 trials, LCH-I showed a higher recurrence rate and higher frequency of diabetes insipidus. This raised the question of whether more aggressive therapy in patients with high-risk disease would provide a therapeutic advantage.59

The AIEOP-CNR-HX and DAL-HX 83/90 trials, LCH-I, attempted to answer this question in a randomized fashion. The results of this study are still under analysis although preliminary evaluations led to the following conclusions:

1. response by 12 weeks of therapy is an important prognostic factor;
2. etoposide plus vinblastine and steroids does not appear to confer any benefit over therapy with vinblastine and steroids;
3. prolonged therapy may decrease the reactivation rate of LCH.

In light of the risk of therapy-associated acute myelogenous leukemia/myelodysplastic syndrome in patients treated with epipodophyllotoxins (i.e., etoposide/VP-16), this study obviated the use of etoposide in LCH. This trial also confirmed that age less than 2 years without risk-organ involvement is not an independent prognostic factor. The Histiocyte Society protocol LCH-II is attempting to determine in a randomized design whether (i) intensified induction therapy, with the addition of intermediate-dose methotrexate followed by inclusion of methotrexate in maintenance therapy, improves remission induction rates and overall outcomes and (ii) whether prolonging continuation therapy reduces the rate of disease reactivation (see Fig. 15.9 for treatment
Group 1: multisystem "risk" patients

Arm A

Vinblastine
Prednisone
6MP

Intermediate response or worse

No active disease

12 months

Arm B

ID-MTX/LR

Intermediate response or worse

Oral MTX

No active disease

12 months

Group 2: multisystem low-risk patients

Vinblastine
Prednisone

Intermediate response or worse

No active disease

6 months

12 months

Group 3: multifocal bone disease and special sites

Vinblastine
Prednisone

Intermediate response or worse

No active disease

6 months

Details of chemotherapy by symbols

Vinblastine 6 mg/m² per week × 6 weeks
Prednisone 40 mg/m² per day × 4 weeks then taper over 2 weeks
Methotrexate 500 mg/m² with leukovorin rescue on weeks 1, 3, 5

Vinblastine 6 mg/m² per week × 6 weeks
Prednisone 40 mg/m² per day × 3 days each week × 6 weeks
Methotrexate 500 mg/m² with leukovorin rescue on weeks 1, 3, 5

Vinblastine 6 mg/m² per week × 6 weeks
Prednisone 40 mg/m² per day × 5 days each 3-week cycle

6-Mercaptopurine (6MP) 50 mg/m² per day for 12 months

Methotrexate (MTX) 500 mg/m² with leukovorin rescue on weeks 1, 3, 5

Fig. 15.9 Treatment arms for LCH-III protocol sponsored by the Histiocyte Society.
the use of a nonablative preparative regimen for HSCT.69 alone or in combination with cytosine arabinoside.61–64 2-
significant experience with the nucleoside analog 2-CDA,
12% and pulmonary insufficiency in 10%.41 Others have
of patients developed long-term complications, patients
to sites of original disease involvement. In one study, 42%
late effects in survivors of LCH tend to be directly related
disease.
Survivorship issues
Survivors of LCH can have significant late sequelae related to
their disease after achieving remission and long-term cure. Late
effects in survivors of LCH tend to be directly related to
sites of original disease involvement. In one study, 42%
of patients developed long-term complications, patients
with multisystem disease being at highest risk. Diabetes
insipidus developed in 15% of patients, CNS complications in
12% and pulmonary insufficiency in 10%.41 Others have
noted neurocognitive problems such as intellectual impair-
ment, psychological problems and psychomotor retardation
in long-term survivors of LCH.48–50 The late CNS complica-
tions of LCH also include neurodegenerative changes that
can be highly disabling.48–50 The neurodegenerative
disease is thought to be the result of a paraneoplastic process
and pathologically is characterized by an inflammatory infiltrate
dominated by CD8-positive reactive lymphocytes, microglial
activation and gliosis. This contrasts with the T-cell infiltra-
tion and severe neurodegeneration surrounding CD1a infl-
itrates of CNS parenchyma.48 Sclerosing cholangitis and liver
failure necessitating liver transplant are also well recognized
late effects of systemic LCH. The role of chemotherapy in the
management of CNS and hepatic sequelae is limited as these
complications appear to be related to an aberrant immune
response and tissue fibrosis as opposed to active LCH.47,48
Patients with LCH also have an increased risk of malignancy,
which may be further increased when treated with etoposide
or radiation as part of their therapy.33,34,76
It is critical for patients with LCH, especially multisystem
disease, to be followed on a long-term basis at a center famil-
lar with the care of patients with LCH. Follow-up should
include imaging studies in addition to routine blood counts,
liver and thyroid function testing as well as urine and elec-
trolyte levels for assessment of diabetes insipidus. Formal
neurocognitive evaluations should be done in patients with
suspected or proven CNS involvement.

Non-Langerhans cell (class I) histiocytes
Juvenile xanthogranulomatous disease and related disorders
The non-Langerhans cell (class I) histiocytic disorders repres-
sent a spectrum of disease defined by the accumulation of
dendritic cells that do not meet the phenotypic criterion for
diagnosis of LCH. These histiocytes, like LCH cells, pheno-
typically resemble a stage in the normal development of
dendritic cells. It is believed that under growth factor stimu-
lation, a common progenitor can develop along two separate
differentiative pathways that can be phenotypically dis-
tinguished by the expression of CD14. The CD14-negative
lineage, under the influence of TNF-α and GM-CSF, differen-
tiates into Langerhans cells while the CD14-positive lineage
can give rise to either cells of the monocyte–macrophage
lineage or to interstitial/dermal dendrocytes.77 Disorders
arising from the monocyte–macrophage lineage are categor-
zied as the class II or macrophage-related histiocytes.
However, the non-Langerhans cell (class I) histiocytes are
believed to arise from dermal dendritic cells. It is critical to
emphasize that disorders arising from the dermal dendrocyte
are now considered class I histiocytes.
The non-Langerhans cell (class I) histiocytes are histologi-
cally nonmalignant proliferative disorders that have variable

Histocytic disorders
clinical presentations. However, these disorders are all defined by the similar pathologic finding of a histiocytic proliferation that is CD1a and S100 negative but factor XIII, CD31, CD68, CD163, fascin and CD14 positive (Fig. 15.10). Clinical presentation of these disorders is variable and appears to be age dependent. It has been hypothesized that the clinical presentation of these disorders, much like LCH, depends on the variable local cytokine milieu.78 Weitzman and Jaffe77 have suggested that the non-Langerhans cell (class I) histiocytoses be divided into three major groups based on their clinical presentation for ease of classification: (i) disorders primarily affecting skin (cutaneous); (ii) cutaneous disorders that have a systemic component; and (iii) multisystem disorders that can also affect skin.

The juvenile xanthogranuloma (JXG) family of diseases represents the most common disorder of this subtype. Juvenile xanthogranulomatous disease is the prototypical member of this family of disorders and the most common form observed in pediatrics. The primary presentation of JXG in children is cutaneous (Fig. 15.11), although approximately 4% of children may also have systemic involvement of the CNS, liver, lungs and eyes.79,80 JXG lesions typically self-involute, although systemic disease may sometimes necessitate chemotherapy.77 Optimal therapy for patients with systemic JXG who need therapeutic intervention remains unclear, although LCH regimens have been most commonly used with variable responses observed.79,81,82 Interestingly, a triple association between JXG, juvenile myelomonocytic leukemia and neurofibromatosis type I has been reported, possibly genetically linking these conditions in some patients.83–86

Fig. 15.10 Histopathology and immunochemical staining of juvenile xanthogranulomatous disease. (a) Juvenile xanthogranuloma characterized by oval, partially lipidized histiocytes admixed with eosinophils (hematoxylin and eosin staining) (original magnification ×200). Many juvenile xanthogranulomas also contain Touton-type multinucleated giant cells. Unlike Langerhans cell histiocytosis, juvenile xanthogranulomas do not express CD1a (b, original magnification ×400) but do express histioyte antigens CD68 (c, original magnification ×400) and CD31 (d, original magnification ×400). Photographs courtesy of Dr John Reith, Department of Pathology, University of Florida School of Medicine, Gainesville, FL, USA.

Fig. 15.11 Extensive cutaneous involvement of an infant with juvenile xanthogranulomatous disease.

Erdheim–Chester disease is also a member of the class I non-Langerhans cell histiocytoses and can often present as a systemic disease. This disease is extremely rare in the pediatric age group and patients are typically older than 50 years of age. Clinically, this disease presents with xanthoma-like skin nodules and bilateral lower extremity bone pain. Radiography shows symmetrical sclerosing bone lesions typically affecting the metaphyseal ends of long bones. Patients with disseminated disease may have severe cardiopulmonary insufficiency from parenchymal involvement of the heart and lung tissues, renal insufficiency due to perinephric involvement, and CNS involvement with ataxia, diabetes insipidus and mental status changes.85,86 This disease is frequently progressive and fatal. Limited success has been reported when treating patients with Erdheim–Chester disease with standard LCH therapy, although anecdotal
cases of response to low-dose IFN-α are notable but in need of prospective confirmation.91

Disorders of varied biological behavior: macrophage-related (class II) histiocytoses

Histiocytic disorders

353

Histiocytic disorders

353

Histiocytic disorders

Hemophagocytic lymphohistiocytosis

Biology

Class II histiocytic disorders are all characterized by the abnormal accumulation of activated macrophages along with lymphocytes in tissues. The predominant member of the class II histiocytoses is hemophagocytic lymphohistiocytosis (HLH), a disorder characterized by the abnormal accumulation of T lymphocytes and macrophages in normal tissues. HLH is further subdivided as follows:

1. primary HLH (familial erythrophagocytic lymphohistiocytosis), a heritable autosomal recessive disorder;
2. secondary HLH, a sporadic disease typically associated with a preexisting inflammatory condition such as infection (infection-associated hemophagocytic syndrome), malignancy (malignancy-associated hemophagocytic syndrome) or immunosuppressive therapy (macrophage activation syndrome).

Primary and secondary HLH are clinically indistinguishable. The presentation of these disorders is typically fulminant and consists of fever, cytopenias, hepatosplenomegaly, hyperbilirubinemia, hyperlipidemia, hypofibrinogenemia, coagulopathy, hemophagocytosis and CNS abnormalities such as seizures.90,91 A family history of consanguinity and age <2 years at time of onset are highly suggestive of primary/inherited HLH. Positive genetic testing for genes known to cause HLH establishes the diagnosis of the primary or inherited form of the disease.

The immunologic defect underlying primary HLH is low or absent natural killer (NK) cell and cytotoxic T-lymphocyte function and number.92,93 This diminished cytotoxic function is responsible for the pathologic expansion of cellular immune responses and infiltration of tissues by inflammatory cells.

This accumulation of activated macrophages and lymphocytes in tissues is perpetuated by the release of inflammatory cytokines by both lymphocytes and antigen-presenting cells, resulting in systemic hypercytokinemia which in turn contributes to organ damage and the signs and symptoms of HLH.94,95

Mutations in three genes have now been identified in patients with primary HLH: PRF1 (perforin),99 UNC13-D (Munc13-4),100 and STX11 (syntaxin 11).99–101 Perforin is stored in cytotoxic granules of NK cells and cytotoxic T cells and is released to the cell surface during the formation of an immunologic synapse, where it functions to create pores in the cytoplasmic membranes of target cells leading to cell death. Munc13-4 and syntaxin 11 are both involved in the stabilization and transport of cytotoxic granules in NK and T cells. Normal NK-cell and T-cell function is crucial in the clearance of infections, particularly viral infections through lysis of infected cells.102,103 The association of PRF1, UNC13-D and STX11 mutations with HLH and the observed NK-cell defects in patients with HLH clearly point to the central role of this pathway in the pathogenesis of HLH. Furthermore, in vitro NK-cell enumeration and cytotoxicity data suggest significant variability among patients with HLH that is directly related to the nature of their genetic defect.104

Incidence and epidemiology

The incidence of primary HLH is estimated to be around 1 in 50 000–300 000 live births based on several retrospective epidemiologic studies.112–114 However, these estimations may

Table 15.3 Genetic defects in primary and secondary hemophagocytic lymphohistiocytosis.

<table>
<thead>
<tr>
<th>Disease</th>
<th>Associated gene</th>
<th>Gene function</th>
<th>Chromosomal location</th>
</tr>
</thead>
<tbody>
<tr>
<td>FHLH-1</td>
<td>Unknown</td>
<td>Unknown</td>
<td>9q21.3–q22</td>
</tr>
<tr>
<td>FHLH-2</td>
<td>PRF1</td>
<td>Induction of apoptosis</td>
<td>10q21–q22</td>
</tr>
<tr>
<td>FHLH-3</td>
<td>UNC13-D</td>
<td>Vesicle priming</td>
<td>17q25</td>
</tr>
<tr>
<td>FHLH-4</td>
<td>STX11</td>
<td>Vesicle transport; t-SNARE</td>
<td>6q24</td>
</tr>
<tr>
<td>GS-2</td>
<td>RAB27A</td>
<td>Vesicle transport; small GTPase</td>
<td>15q21</td>
</tr>
<tr>
<td>CHS-1</td>
<td>LYST</td>
<td>Vesicle transport; not further defined</td>
<td>1q22–1q24</td>
</tr>
<tr>
<td>XLP</td>
<td>SH2D1A</td>
<td>Signal transduction and activation of lymphocytes</td>
<td>Xq25</td>
</tr>
</tbody>
</table>

CHS, Chédiak–Higashi syndrome; FHLH, familial hemophagocytic lymphohistiocytosis; GS, Griscelli syndrome; XLP, X-linked lymphoproliferative syndrome. Adapted with permission from Janka G, zur Stadt U. Hematology (Am Soc Hematol Educ Program) 2005; 82–8.
underestimate the true incidence of HLH secondary to lack of familiarity of many primary physicians with this diagnosis. Interestingly, the prevalence of primary HLH is noted to be geographic in distribution, a finding attributed to the familial nature and the founder effect seen in this disease. The majority of cases of primary HLH occur within the first year of life, although cases have been reported as late as the third decade of life. Secondary HLH, however, occurs sporadically and can be seen at any age depending on the primary initiating event. The male to female ratio of primary HLH is estimated to be 1:1, with some studies suggesting a slight male predominance.

Clinical presentation
HLH is fatal if the diagnosis is delayed and appropriate therapy not instituted rapidly. The most common presenting symptoms include fever and hepatosplenomegaly, although rash, lymphadenopathy and CNS symptoms are common. Signs and symptoms also include cytopenias, transaminases, coagulopathy, hypofibrinogenemia, hypertriglyceridemia, and evidence of hemophagocytosis from bone marrow aspiration (Fig. 15.12). As significant variability in clinical presentation may impede diagnosis, specific diagnostic criteria have been established by the Histiocyte Society to aid in more expeditious diagnosis and treatment (Table 15.4). In particular, some children may present with solely or primarily CNS-related symptoms; in these children a high level of suspicion on observing characteristic brain MRI changes is important in making an early diagnosis. If strong clinical suspicion is present, it is recommended that therapy be initiated even if all criteria are not fully satisfied.

In such cases, bone marrow studies should be repeated if initially negative to help establish a diagnosis by documenting hemophagocytosis. The presence of a family history positive for consanguinity or another affected sibling as well as the availability of molecular testing for gene mutations can further assist in establishing a diagnosis.

Treatment
Current therapy of HLH, as prescribed by the HLH-2004 protocol of the Histiocyte Society, consists of dexamethasone, etoposide and cyclosporin in combination with intrathecal methotrexate and prednisolone when indicated by the presence of cerebrospinal fluid pleocytosis. Antithymocyte globulin has also been used, but mostly as second-line therapy. Primary HLH tends to be recurrent and does not permanently respond to chemotherapy, thus necessitating HSCT for cure. However, secondary HLH, with the exception of refractory cases, can often be effectively treated with chemotherapy or immunomodulatory approaches such as intravenous immunoglobulin. Treatment of an underlying infection or malignancy, while necessary, may be inadequate in cases of secondary HLH, necessitating HLH-type therapy. Thus, in cases of infection-associated or malignancy-associated HLH, there is often a need to sequentially treat both the HLH and the underlying disorder in order to achieve complete remission. HSCT is usually necessary in patients with recurrent secondary HLH.

The current Histiocyte Society international study. HLH-2004, is based on the HLH-94 study. The HLH-94 protocol
achieved an estimated survival rate of 55% at a median of about 3 years of follow-up. This rate was slightly lower in patients with familial HLH (51%), although patients who underwent bone marrow transplantation had a 3-year survival probability of 62%. As a significant number of patients on HLH-94 died prior to receiving bone marrow transplantation, the HLH-2004 protocol has been modified so that cyclosporin is administered concurrently with dexamethasone and etoposide at the beginning of therapy with the goal of improving on the early treatment failure rate.66

Survivorship issues

The primary long-term sequelae of HLH are mainly related to the extent of CNS involvement. Prompt initiation of systemic therapy is critical for reducing CNS morbidity in HLH. Although the benefits of intrathecal therapy have not been clinically proven, inclusion of intrathecal therapy in patients with documented CNS disease is recommended.91,127–129 Close follow-up of neurologic function is critical in order to assess the developmental delay that has been observed in these patients. It remains unclear if the neurologic complications are a direct result of disease involvement, therapy or infectious complications.130 Long-term follow-up is a critical part of the care of HLH patients and should include observation for CNS effects, bone marrow transplant-related morbidities, and secondary acute myeloid leukemia related to the use of etoposide.131

Sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease)

Other members of the class II histiocytoses tend to have a more indolent course than HLH. Sinus histiocytosis with massive lymphadenopathy (SHML), also known as Rosai-Dorfman disease, is characterized by a lymphohistiocytic accumulation in the sinuses of lymph nodes without architectural effacement.132,133 The proliferative macrophages seen in this disorder are typically S100 positive but CD1a negative and can be characteristically observed to wrap around intact lymphocytes or other cells, a process known as emperipoleisis. SHML has a predilection for lymph nodes of the head and neck but can be seen in any organ including the CNS.134–137 SHML more commonly occurs in patients of African ancestry; and is not typically responsive to most therapeutic approaches.138 Recent reports have documented response to therapy with high-dose dexamethasone and also with 2-CDA.133,139,140 Although SHML can be potentially disfiguring, it is only rarely life-threatening.

Malignant (class III) histiocytoses

This class of disorders consists of malignant histiocytosis, histiocytic sarcoma and acute monocytic leukemia. For the most part, these disorders can be characterized by malignant transformation of cells of the MPS with significant cellular atypia. Those disorders characterized by malignant transformation of dendritic cells are often treated with lymphoma/leukemia protocols, including HSCT, although outcomes remain relatively poor. The wide variety of these conditions, the rarity of occurrence in pediatrics, and discussion elsewhere in this book (see Chapter 16) preclude a more detailed discussion here.

Challenges

Important landmarks have been achieved in our understanding of LCH since the first descriptions from the 1800s. We have a better understanding of the normal and abnormal responses of cells belonging to the MPS as well as of the etiology, presentation, natural history and treatment of LCH. Nevertheless, large numbers of patients remain undiagnosed or inadequately treated or simply do not respond to current therapies. The outcome for patients with LCH, particularly with refractory disease or disease involving organs such as the bone marrow, liver, lung and CNS, remains poor. The cure rate of HLH still remains close to 50%, with many survivors having significant adverse long-term sequelae. The formation of the Histiocyte Society has helped establish a framework within which collaborative studies can be undertaken. Future efforts should focus on further defining the etiology of LCH and understanding the molecular pathways with the goal of identifying molecular targets for more effective treatment and improved outcomes. Additionally, improved clinical understanding of the natural history of the histiocytoses is an important key to early diagnosis and appropriate therapy. Cooperative group clinical trials involving multidisciplinary approaches, particularly involving medical and pediatric oncologists, should help establish future improvements in outcome for patients with histiocytosis.

References

Chapter 15

11. Laman JD, Leenen PJ, Annels NE, Hogendoorn PC, Egeler RM.
12. Fleming MD, Pinkus JL, Fournier MV.
13. Egeler RM, Favara BE, van Meurs M, Laman JD, Claassen E.
14. Steinman RM, Cohn ZA. Identification of a novel cell type in
21. Valledor AF, Borras FE, Cullell-Young M, Celada A.
19. Guerriero A, Langmuir PB, Spain LM, Scott EW. PU.1 is
20. Anderson KL, Perkin H, Sarh CD, Venturini S, Maki RA,
18. Abbas A, Lichtman AH, Jordan SP. Cells and tissues of the
8. Riches D. Monocytes, macrophages and dendritic cells of the
26. Nezelof C, Basset F. An hypothesis for Langerhans cell
28. Arico M, Clementi R, Caselli D, Danesino C. Histiocytic
15. Geissmann F, Lepelletier Y, Fraitag S
36. Bernstrand C, Carstensen H, Jakobsen B, Svejgaard A, Henter
30. Yu RC, Chu C, Buluwela L, Chu AC. Clonal proliferation of
37. Schouten B, Egeler RM, Leenen PJ, Taminiau AH, van den
32. Dacie S, Trusky C, Bakker A, Finkelstein SD, Yousem SA.
35. Glotzbecker MP, Carpentieri DF, Dormans JP. Histiocytic
38. Willman CL, Busque L, Griffith BB. The relation of Langerhans
40. Yu RC, Chu C, Buluwela L, Chu AC. Clonal proliferation of
29. Willman CL, Busque L, Griffith BB et al. Langerhans’ cell
19. Guerriero A, Langmuir PB, Spain LM, Scott EW. PU.1 is
24. Kannourakis G, Abbas A. The role of cytokines in the
25. Emile JF, Fraigtat S, Andry P, Leborgne M, Lellouch-Tubiana A,
22. Nezelof C, Basset F, Rousseau MF. Histiocytosis X. histogenetic
23. Geissmann F, Lepelletier Y, Fraigtat S et al. Differentiation of
20. Anderson KL, Perkin H, Surh CD, Venturini S, Maki RA,
24. Kannourakis G, Abbas A. The role of cytokines in the
25. Emile JF, Fraigtat S, Andry P, Leborgne M, Lellouch-Tubiana A,
22. Nezelof C, Basset F, Rousseau MF. Histiocytosis X. histogenetic
Riches D. Monocytes, macrophages and dendritic cells of the
11. Laman JD, Leenen PJ, Annels NE, Hogendoorn PC, Egeler RM.
14. Fleming MD, Pinkus JL, Fournier MV.
13. Egeler RM, Favara BE, van Meurs M, Laman JD, Claassen E.
15. Geissmann F, Lepelletier Y, Fraitag S
36. Bernstrand C, Carstensen H, Jakobsen B, Svejgaard A, Henter
30. Yu RC, Chu C, Buluwela L, Chu AC. Clonal proliferation of
37. Schouten B, Egeler RM, Leenen PJ, Taminiau AH, van den
32. Dacie S, Trusky C, Bakker A, Finkelstein SD, Yousem SA.
35. Glotzbecker MP, Carpentieri DF, Dormans JP. Histiocytic
38. Willman CL, Busque L, Griffith BB et al. Langerhans’ cell
40. Yu RC, Chu C, Buluwela L, Chu AC. Clonal proliferation of
29. Willman CL, Busque L, Griffith BB et al. Langerhans’ cell
19. Guerriero A, Langmuir PB, Spain LM, Scott EW. PU.1 is
24. Kannourakis G, Abbas A. The role of cytokines in the
25. Emile JF, Fraigtat S, Andry P, Leborgne M, Lellouch-Tubiana A,
22. Nezelof C, Basset F, Rousseau MF. Histiocytosis X. histogenetic
Riches D. Monocytes, macrophages and dendritic cells of the
11. Laman JD, Leenen PJ, Annels NE, Hogendoorn PC, Egeler RM.
14. Fleming MD, Pinkus JL, Fournier MV.
13. Egeler RM, Favara BE, van Meurs M, Laman JD, Claassen E.
15. Geissmann F, Lepelletier Y, Fraitag S
36. Bernstrand C, Carstensen H, Jakobsen B, Svejgaard A, Henter
30. Yu RC, Chu C, Buluwela L, Chu AC. Clonal proliferation of
37. Schouten B, Egeler RM, Leenen PJ, Taminiau AH, van den
32. Dacie S, Trusky C, Bakker A, Finkelstein SD, Yousem SA.
35. Glotzbecker MP, Carpentieri DF, Dormans JP. Histiocytic
38. Willman CL, Busque L, Griffith BB et al. Langerhans’ cell
40. Yu RC, Chu C, Buluwela L, Chu AC. Clonal proliferation of
29. Willman CL, Busque L, Griffith BB et al. Langerhans’ cell
19. Guerriero A, Langmuir PB, Spain LM, Scott EW. PU.1 is
24. Kannourakis G, Abbas A. The role of cytokines in the
25. Emile JF, Fraigtat S, Andry P, Leborgne M, Lellouch-Tubiana A,
22. Nezelof C, Basset F, Rousseau MF. Histiocytosis X. histogenetic
Riches D. Monocytes, macrophages and dendritic cells of the
11. Laman JD, Leenen PJ, Annels NE, Hogendoorn PC, Egeler RM.
14. Fleming MD, Pinkus JL, Fournier MV.
13. Egeler RM, Favara BE, van Meurs M, Laman JD, Claassen E.
15. Geissmann F, Lepelletier Y, Fraitag S
36. Bernstrand C, Carstensen H, Jakobsen B, Svejgaard A, Henter
30. Yu RC, Chu C, Buluwela L, Chu AC. Clonal proliferation of
37. Schouten B, Egeler RM, Leenen PJ, Taminiau AH, van den
32. Dacie S, Trusky C, Bakker A, Finkelstein SD, Yousem SA.
35. Glotzbecker MP, Carpentieri DF, Dormans JP. Histiocytic
38. Willman CL, Busque L, Griffith BB et al. Langerhans’ cell
40. Yu RC, Chu C, Buluwela L, Chu AC. Clonal proliferation of
29. Willman CL, Busque L, Griffith BB et al. Langerhans’ cell
19. Guerriero A, Langmuir PB, Spain LM, Scott EW. PU.1 is
24. Kannourakis G, Abbas A. The role of cytokines in the
25. Emile JF, Fraigtat S, Andry P, Leborgne M, Lellouch-Tubiana A,
Chapter 15


108. Trapani JA, Davis J, Sutton VR, Smyth MJ. Proapoptotic...


Histiocytic disorders